FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Revolution Medicines, Inc. Warrant Stock AnalysisComprehensive stock analysis for Revolution Medicines, Inc. Warrant (RVMDW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRVMDW
RVMDW
Revolution Medicines, Inc. Warrant
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RVMDW
Home🔹Stocks🔹Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. Warrant

RVMDW•NASDAQ

Revolution Medicines, Inc. Warrant

RVMDW•NASDAQ
Market cap
$45.46B
Sentiment

Your view on RVMDW

Mkt Cap
$45.46B
Sentiment
Your view
RVMDW
Revolution Medicines, Inc. Warrant
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RVMDW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Revolution Medicines, Inc. Warrant

Industry
Biotechnology
Sector
Healthcare
CEO
Mark A. Goldsmith
Headquarters
700 Saginaw Drive, Redwood City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Mark A. Goldsmith
Headquarters
700 Saginaw Drive, Redwood City, CA, US
Description

Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds. Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D). Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets. In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Revolution Medicines, Inc. Warrant, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Revolution Medicines, Inc. Warrant. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Revolution Medicines, Inc. Warrant. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Revolution Medicines, Inc. Warrant. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Revolution Medicines, Inc. Warrant. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Revolution Medicines, Inc. Warrant valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Revolution Medicines, Inc. Warrant, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Revolution Medicines, Inc. Warrant executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Revolution Medicines, Inc. Warrant. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Revolution Medicines, Inc. Warrant. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Revolution Medicines, Inc. Warrant. Press releases and market coverage, newest first.

News

Latest Market News